Abstract
This study provides an example of how healthcare system-wide progress in implementation of opioid-therapy guideline recommendations can be longitudinally assessed and then related to subsequent opioid-prescribed patient health and safety outcomes. Using longitudinal linear mixed effects analyses, we determined that in the Department of Veterans Affairs (VA) healthcare system (n = 141 facilities), over the 4-year interval from 2010 to 2013, a key opioid therapy guideline recommendation, urine drug screening (UDS), increased from 29 to 42 %, with an average within-facility increase rate of 4.5 % per year. Higher levels of UDS implementation from 2010 to 2013 were associated with lower risk of suicide and drug overdose events among VA opioid-prescribed patients in 2013, even after adjusting for patients’ 2012 demographic characteristics and medical and mental health comorbidities. Findings suggest that VA clinicians and healthcare policymakers have been responsive to the 2010 VA/Department of Defense (DOD) UDS treatment guideline recommendation, resulting in improved patient safety for VA opioid-prescribed patients.
Similar content being viewed by others
References
Centers for Disease Control and Prevention. CDC grand rounds: prescription drug overdoses—A U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012; 61: 10-13.
Daubresse M, Chang H-Y, Yu Y, et al. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000–2010. Med Care. 2013; 51: 870-878.
Substance Abuse and Mental Health Service Administration, Office of Applied Studies. Drug Abuse Warning Network, 2007: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD; 2010.
Nuckols TK, Anderson L, Popescu I, et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014; 160: 38-47.
Cheatle MD. Depression, chronic pain, and suicide by overdose: on the edge. Pain Med. 2011; 12: S43-S48.
Rudd RA, Paulozzi LJ, Bauer MJ, et al. Increases in heroin overdose deaths—28 states 2010 to 2012. MMWR Morb Mortal Wkly Rep. 2014; 63: 834-849.
Midboe AM, Lewis ET, Paik MC, et al. Measurement of adherence to clinical practice guidelines for opioid therapy for chronic pain. Transl Behav Med. 2012; 2: 57-64.
The Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD clinical practice guideline for management of opioid therapy for chronic pain. Washington, DC: The Office of Quality and Performance, VA and Quality Management Directorate, US Army MEDCOM; 2003. Available at: http://www.va.gov/painmanagement/docs/chronicpainguidelinesva2003.pdf. Accessibility verified June 20, 2016.
Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10: 113-130.
The Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD clinical practice guideline for management of opioid therapy for chronic pain [U.S. Department of Veterans Affairs web site]. May, 2010. Available at: http://www.healthquality.va.gov/guidelines/Pain/cot/. Accessibility verified November 2, 2015.
Volkow ND, McLellan AT. Opioid abuse in chronic pain—misconceptions and mitigation strategies. N Engl J Med. 2016; 374: 1253-1263.
Franklin GM. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology. 2014; 83: 1277-1284.
Starrels JL, Becker WC, Alford DP, et al. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010; 152: 712-720.
Canada RE, DiRocco D, Day S. A better approach to opioid-prescribing in primary care. J Fam Pract. 2014; 63: E1-E8.
Fagan MJ, Chen JT, Diaz JA, et al. Do internal medicine residents find pain medication agreements useful? Clin J Pain. 2008; 24: 35-38.
Touchet BK, Yates WR, Coon KA. Opioid contract use associated with physician training level and practice specialty. J Opioid Manag. 2005; 1: 195-200.
Im JJ, Shachter RD, Oliva EM, et al. Association of care practices with suicide attempts in US Veterans prescribed opioid medications for chronic pain management. J Gen Intern Med. 2015; 30: 979-991.
Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision, Sixth Edition. 2011.
Elixhauser A, Steiner C, Harris D, et al. Comorbidity measures for use with administrative data. Med Care. 1998; 36: 8-27.
Nock MK, Hwang I, Sampson NA, et al. Mental disorders, comorbidity and suicidal behavior: results from the National Comorbidity Survey Replication. Mol Psychol. 2010; 15: 868-76.
Seal KH, Shi Y, Cohen G, et al. Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. JAMA. 2012; 7: 940-7.
Bates D, Maechler M, Bolker BM et al. (2014). Lme4: Linear mixed-effects models using Eigen and S4. Available at: http://arxiv.org/abs/1406.5823. Accessibility verified November 2, 2015.
R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: http://www.R-project.org/. Accessibility verified November 2, 2015.
Bryk SW, Raudenbush AS. Hierarchical Linear Models: Applications and Data Analysis Methods. Thousand Oaks, CA: Sage Publications; 2002.
Singer JD, Willett JB. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. Oxford, UK: Oxford University Press; 2003.
Buscaglia AC, Paik MC, Lewis E, et al. Baseline variation in use of VA/DOD clinical practice guideline recommended opioid prescribing practices across VA health care systems. Clin J Pain. 2015; 31: 803-812.
Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 2007; 37: 301-314.
Single topic issue: quality and utility of secondary data for VA research. J Rehabil Res Dev. 2010; 47.
U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. National Action Plan for Adverse Drug Event Prevention. Washington, DC: USDHHS; 2014.
Acknowledgments
This work was supported in part by a VA HSR&D QUERI grant RRP 10-106. We thank the VA Opioid Metric Development Team (William Becker, Rollin Gallagher, Francine Goodman, Patricia Henderson, James Im, Robert Kerns, Amanda Midboe, and Jack Rosenberg) for their work developing the measures used in this study, Amanda Midboe for her helpful comments on an earlier version of this manuscript, and Sonya SooHoo for assisting with manuscript preparation. The views expressed here are those of the authors and do not necessarily reflect positions or policies of the Department of Veterans Affairs or of the US government.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Research reported here was supported in part by the Department of Veterans Affairs Health Services Research and Development (HSR&D) grant number RRP 10-106. All work performed in this investigation was in accordance with the ethical standards of our institutional research committees and with the 1964 Helsinki Declaration and its later amendments. For this type of study, formal consent is not required. This research was approved by the Stanford University administrative panels for the protection of human subjects.
Conflict of Interest
The authors declare that they have no conflicts of interest.
Additional information
Implications
For researchers, this study provides an example of how healthcare system-wide electronic patient treatment data can be used to operationalize and measure patient treatment guideline implementation and the use of a longitudinal linear mixed effects statistical approach to determine associations between implementation metrics and patient health and safety outcomes. For clinicians, this study contributes to the evidence base for urine drug screening as a promising tool for improving opioid-prescribed patient safety. For healthcare providers and policy makers, results of studies such as this can help guide clinical practices and healthcare system resource allocations that better balance the desire to provide patients with accessible, effective relief for pain with evidence-based practices that protect them from adverse medical events associated with opioid therapy.
About this article
Cite this article
Brennan, P.L., Del Re, A.C., Henderson, P.T. et al. Healthcare system-wide implementation of opioid-safety guideline recommendations: the case of urine drug screening and opioid-patient suicide- and overdose-related events in the Veterans Health Administration. Behav. Med. Pract. Policy Res. 6, 605–612 (2016). https://doi.org/10.1007/s13142-016-0423-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13142-016-0423-7